Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial

doi:10.12998/wjcc.v11.i21.5083

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3758)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

2174

Figures (1-8)

333

Tables (1-3)

186

Sum=2813

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

174

Download

576

Sum=750

Jul 26, 2023 (publication date) through Nov 12, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Cases. Jul 26, 2023; 11(21): 5083-5096
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5083

Table 2 Baseline characteristics of participants

Variable	All patients	Placebo group	hUC-MSC group	Z	P value
Variable	n = 34	n = 10	n = 24	Z	P value
Sex					0.45
Male	28 (82.4)	8 (80.0)	20 (83.3)
Female	6 (17.6)	2 (20.0)	4 (16.7)
Age in yr	52 (45.5, 56.0)	49.0 (44.0, 58.5)	52.0 (46.0, 56.0)	-0.19	0.85
Duration of T2DM in yr	10.00 (4.00, 14.00)	7.00 (3.75, 11.75)	10.00 (4.50, 14.00)	-0.97	0.33
BMI in kg/m²	24.21 (23.34, 26.25)	23.72 (23.00, 26.25)	24.61 (23.25, 26.50)	-0.42	0.68
FPG in mmol/L	8.95 (8.13, 10.14)	8.82 (7.81, 9.97)	9.13 (8.18, 11.91)	-0.42	0.68
HbA1c as %	7.95 (7.40, 8.50)	8.00 (7.28, 8.35)	7.95 (7.45, 8.50)	-0.49	0.70

Data are presented as median (minimum, maximum) or number of cases (percentage). BMI: Body mass index; FPG: Fasting plasma glucose; HbA1c: Glycosylated hemoglobin; hUC-MSC: Human umbilical cord-mesenchymal stem cell; T2DM: Type 2 diabetes mellitus.

Citation: Lian XF, Lu DH, Liu HL, Liu YJ, Yang Y, Lin Y, Xie F, Huang CH, Wu HM, Long AM, Hui CJ, Shi Y, Chen Y, Gao YF, Zhang F. Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial. World J Clin Cases 2023; 11(21): 5083-5096
URL: https://www.wjgnet.com/2307-8960/full/v11/i21/5083.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i21.5083